More than 1 in every 3 — some 40 percent — of Parkinson’s patients have “off periods,” the return of motor and non-motor symptoms as the effectiveness of a treatment’s dose wears off. Artworks created in collaboration with patients, part of an Acorda Therapeutics program, are helping to…
News
Parkinson’s disease-related protein Parkin may rely on another protein called MITOL to repair damaged mitochondria, the small organelles that provide energy to cells and, when defective, can damage brain nerve cells. Understanding these molecular mechanisms may help improve Parkinson’s therapies that intend to boost Parkin activity. The study…
A new study highlights some of the differences in perspective on disease management between people living with Parkinson’s disease and doctors treating them. The study looks at non-motor symptoms, method of medication delivery, and awareness of support services as places where doctors’ and patients’ perceptions don’t line up, and suggests…
Connexin-32 — a protein found in small channels between nerve cells and involved in cell-to-cell communication — works to progress Parkinson’s disease by binding to alpha-synuclein and spreading toxic protein clumps throughout the brain, research suggests. The study, “Binding of α-synuclein oligomers to Cx32 facilitates protein uptake and transfer in…
News
Cleveland Clinic Researcher Gets $3M NIH Grant to Study Impact of Exercise on Parkinson’s Disease
A Cleveland Clinic researcher is getting a $3 million grant from the National Institutes of Health (NIH) to study the long-term impact of high-intensity aerobic exercise on Parkinson’s disease progression. The five-year award goes to Jay Alberts, PhD, a staff member in the department of biomedical…
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded Casma Therapeutics $370,000 to advance an innovative class of therapies aimed at slowing disease progression. The grant will promote the biotechnology company’s investigation into compounds that activate the calcium channel TRPML1 to accelerate autophagy…
UCB has announced the start of a Phase 1b clinical trial to evaluate the efficacy and safety of its therapeutic candidate UCB0599 for the treatment of Parkinson’s disease. This multicenter clinical trial will take place across the United States. Current treatments for Parkinson’s, which include…
Vitamin B12 can prevent the formation of and destroy alpha-synuclein aggregates in the brain, lowering their toxicity and potentially helping to alleviate Parkinson’s disease, according to a study. The study, “Vitamin B12 inhibits α-synuclein fibrillogenesis and protects against amyloid-induced cytotoxicity,” was published in the journal…
Chrysin, a chemical commonly found in plants, may ease behavioral, cognitive, and neurochemical changes in Parkinson’s disease, according to a mouse study. The study, “Chrysin protects against behavioral, cognitive and neurochemical alterations in a 6-hydroxydopamine model of Parkinson’s disease,” was published in Neuroscience Letters. Studies…
Measuring the amount of alpha-synuclein in tiny vesicles collected from blood serum may help diagnose early Parkinson’s and identify patients with different types of this disease. The study with that finding, “Central Nervous System-Derived Exosomal Alpha-Synuclein in Serum May Be a Biomarker in Parkinson’s Disease,” was published…
Recent Posts
- Energy shortage in cells may drive toxic dopamine buildup in Parkinson’s
- Addressing a misconception that levodopa loses effectiveness over time
- New Silvi Foundation funds research into Parkinson’s and related diseases
- New national strategy urges patient-centered Parkinson’s care in US
- When love can’t put things back on track, it finds a new way to keep going